2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

702. CAR-T Cell Therapies: Basic and Translational: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Quality Improvement, Diseases, Immunology, Autoimmune Disorders, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Animal Model
PAPER

4110 Multiplex-engineered iPSC-derived CD19 CAR γδ T cells (BG-I0501) convert human allogeneic immune pressure into a supportive niche, enhancing antitumor activity and functional persistence

Ying-Tsen Tung, Fang-Pei Chang2, Shiou-Ling Jian3, Ke-Hsun Hsu4, Annie Yi-Ting Lai5, Ji-Kuan Wang6, Yi-Chiao Tseng7, Fu-Fei Hsu8, Lien-Szu Wu9, Jen-Chih Chi10, Jeff Ssu-Cheng Hsu11, Ching-Ying Huang12, Alex Shih-Min Huang13
1 BeOne Medicines, Taipei, Taiwan
2 BeOne Medicines, Taipei, Taiwan
3 BeOne Medicines, Taipei, Taiwan
4 BeOne Medicines, Taipei, Taiwan
5 BeOne Medicines, Taipei, Taiwan
6 BeOne Medicines, Taipei, Taiwan
7 BeOne Medicines, Taipei, Taiwan
8 BeOne Medicines, Taipei, Taiwan
9 BeOne Medicines, Taipei, Taiwan
10 BeOne Medicines, Taipei, Taiwan
11 BeOne Medicines, Taipei, Taiwan
12 BeOne Medicines, Taipei, Taiwan
13 BeOne Medicines, Taipei, Taiwan

Autologous CAR-T therapy has transformed treatment of B-cell malignancies but remains limited by patient-specific manufacturing, variable T-cell fitness, prolonged vein-to-vein time, and cost. Donor-derived allogeneic platforms improve availability but may require HLA matching or donor selection to mitigate host rejection and remain constrained by limited persistence, lymphodepletion dependence, and donor variability. In vivo CAR-T approaches may simplify manufacturing but still depend on endogenous immune fitness and precise control of transduction and expansion. These limitations underscore the need for a truly off-the-shelf therapy—built from a standardized cellular source and engineered not merely to evade human allogeneic immune pressure, but to convert it into a therapeutically supportive niche.

BG-I0501 was reproducibly generated from a clonally derived, multiplex-engineered iPSC line using a proprietary γδ T-cell differentiation and expansion process. The iPSC clone incorporated modules for CD19 targeting, allogeneic immune evasion, resistance to activation-induced apoptosis, and enhanced sensitivity to physiologic cytokine levels sufficient to sustain activation and expansion. It also incorporated a signal converter that captures inflammatory cues during tumor killing and translates them into renewed activation and expansion, supporting durable antitumor responses. In vitro, BG-I0501 sustained serial tumor killing through ≥30 rounds of NALM6 rechallenge from a starting effector-to-target (E:T) ratio of 0.4, while producing undetectable-to-low levels of CRS-relevant cytokines, including IL-2 and IL-6—consistent with potent yet controlled effector function. In vivo, in non-tumor-bearing PBMC-humanized NOG-MHC class I/II double-knockout mice, non-engineered iPSC-derived γδ T cells declined rapidly, consistent with allogeneic rejection, whereas BG-I0501 expanded and persisted across 14 donors. Relative to non-humanized mice, BG-I0501 achieved a 12-fold higher mean Cmax, a 24-fold higher mean AUCD0-D32, and more sustained peripheral-blood expansion, with mean levels remaining over four orders of magnitude higher on Day 32 after infusion.

In tumor-bearing non-humanized mice, BG-I0501 reproducibly achieved complete tumor clearance. Strikingly, in tumor-bearing PBMC-humanized mice, BG-I0501 cleared tumors in all treated animals at one-third of the efficacious dose tested in non-humanized mice, despite a two-fold higher tumor burden, with responses maintained for ≥50 days. By contrast untreated NALM6 tumors grew progressively and comparably in both models, indicating that antitumor activity required BG-I0501 and was not attributable to PBMC alone. The distribution pattern was consistent with greater BG-I0501 deployment and retention in disease-relevant tissues in tumor-bearing PBMC-humanized than non-humanized mice. Together, these context-dependent PK, distribution, and efficacy patterns suggest that human PBMC support systemic BG-I0501 expansion without tumor, whereas in tumor-bearing animals the same immune context may favor redistribution to disease sites and sustain local antitumor activity. Accordingly, peripheral-blood PK alone may incompletely capture therapeutically relevant persistence.

In conclusion, BG-I0501 defines a differentiated iPSC-derived allogeneic cell-therapy paradigm in which multiplex-engineered CD19 CAR γδ T cells not only withstand human allogeneic immune pressure, but harness it to enhance expansion, persistence, and antitumor activity. Across diverse human PBMC backgrounds, engineered iPSC-derived γδ T cells outperformed non-engineered γδ T cells, and BG-I0501 achieved durable tumor clearance under reduced-dose and higher-tumor-burden conditions. Its context-dependent distribution—systemic expansion without tumor and potential redistribution toward disease-relevant tissues in tumor-bearing animals—further suggests that peripheral-blood PK may underestimate therapeutically relevant persistence and local antitumor activity. Although PBMC-humanized NOG-MHC class I/II double-knockout mice do not directly recapitulate clinical treatment without lymphodepletion, they provide a stringent human allogeneic immune-pressure setting and support further evaluation of the relationship between allogeneic immune pressure, cell expansion, and antitumor activity. Together, these findings support clinical evaluation of BG-I0501 as a standardized, off-the-shelf CD19 CAR γδ T-cell product for B-cell malignancies.

Alex Shih-Min Huang: BeOne Medicines - Current Employment